Table 1.
Characteristics of study participants
| n=91 | |
|---|---|
| Age(SD),y | 59.5(9.4) |
| Men,n(%) | 56(61.5) |
| Whites,n(%) | 60(65.9) |
| Body mass index,kg/m2 | 30.5(6.9) |
| Hypertension,n(%) | 65(71.4) |
| Diabetes,n(%) | 24(26.4) |
| Current or former smoker,n(%) | 46(50.6) |
| History of MI,n(%) | 14(15.4) |
| History of PCI/CABG,n(%) | 24(26.4) |
| NYHA class≥II,n(%) | 22(24.2) |
| Valvular Heart Diseases (mild),n(%) | 7(13) |
| Systolic BP(SD),mmHg | 144.3(26.2) |
| Diastolic BP(SD),mmHg | 85.1(16.4) |
| eGFR(SD),ml/min/1.73m2 | 90.5(2.6) |
| Beta-blockers,n(%) | 33(36.3) |
| ACE-I or ARBs,n(%) | 36(39.6) |
| Ca-channel blockers,n(%) | 16(17.6) |
| Statins,n(%) | 51(56.0) |
| LA and LV structure and function parameters | |
| LA Volume index max(SD),ml/m2 | 34.8(11.0) |
| LA Volume index min(SD),ml/m2 | 16.7(7.0) |
| Global LAEF,ml/min | 52.9(9.0) |
| LA conduit function(Passive EF) | 28.0(9.0) |
| LA booster pump function(Active EF) | 34.0(14.5) |
| LA reservoir function | 122.3(56.5) |
| Max LA strain(SD), | 26.4(8.6) |
| Max LA strain rate(SD), | 1.18(0.42) |
| LV ejection fraction(SD),% | 60.64(8.6) |
| LV mass index(SD),g/m2 | 64.4(16.7) |
| LV Fibrosis index | 0.51(0.07) |
| ECG parameters | |
| Heart rate(SD),bpm | 65.0(10.7) |
| QRS duration(SD),ms | 104.7(23.5) |
| P-duration(SD),ms | 111.9(13.7) |
| P-axis(SD),deg | 46.8(33.3) |
| PR interval(SD),ms | 181.3(43.1) |
| PTFV1(SD),mV*ms | −3.3(1.9) |
| P-prime amplitude in V1(SD),µV | −46.3(25.1) |
| P-prime duration in V1,ms | 62.7(26.1) |